Influence of induction modality on the outcome of deceased donor kidney transplant recipients discharged on steroid-free maintenance immunosuppression

Transplantation

Volumn 93, Issue 8, 2012, Pages 799-805

  Sureshkumar, Kalathil K ^a   Thai, Ngoc L ^a   Hussain, Sabiha M ^a   Ko, Tina Y ^a   Marcus, Richard J ^a  

^a ALLEGHENY GENERAL HOSPITAL   (United States)

Author keywords

Graft failure risk; Induction agent; Steroid free

Indexed keywords

ALEMTUZUMAB; BASILIXIMAB; CALCINEURIN INHIBITOR; DACLIZUMAB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CADAVER KIDNEY; COLD ISCHEMIA; CONTROLLED STUDY; FEMALE; GRAFT FAILURE; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTILYMPHOCYTE SERUM; CADAVER; CALCINEURIN; FEMALE; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; RECEPTORS, INTERLEUKIN-2; STEROIDS; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84859634507     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3182472898     Document Type: Article

References (20)

1. Cai J, Terasaki PI. Induction immunosuppression improves long-term graft and patient outcome in organ transplantation: An analysis of United Network for Organ Sharing registry data. Transplantation 2010; 90: 1511.
2. Sureshkumar KK, Hussain SM, Zimmer BW, et al. Emerging role of alemtuzumab in renal and renal-pancreas transplantation. Expert Opin Biol Ther 2008; 8: 1605.
3. Knechtle SJ, Fechner JH, Dong Y, et al. Primate renal transplants using immunotoxin. Surgery 1998; 124: 438.
4. Knechtle SJ, Vargo D, Fechner J, et al. FN18-CRM9 immunotoxin promotes tolerance in primate renal allografts. Transplantation 1997; 63: 1.
5. Calne R, Friend P, Moffatt S, et al. Prope tolerance, perioperative Campath-1H, and low-dose cyclosporine monotherapy in renal allograft recipients. Lancet 1998; 351: 1701.
6. Woodle ES, Alloway RR, Buell JF, et al. Multivariate analysis of risk factors for acute rejection in early corticosteroid cessation regimens under modern immunosuppression. Am J Transplant 2005; 5: 2740.
7. Kaufman DB, Leventhal JR, Axelrod D, et al. Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: Comparison with basiliximab induction-long-term results. Am J Transplant 2005; 5: 2539.
8. Shapiro R, Basu A, Tan H, et al. Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with Thymoglobulin or Campath. J Am Coll Surg 2005; 20: 505.
9. Schadde E, Dalesandro AM, Knechtle SJ, et al. Alemtuzumab induction and triple maintenance immunotherapy in kidney transplantation from donors after cardiac death. Transpl Int 2008; 21: 625.
10. Knechtle SJ, Fernandez LA, Pirsch JD, et al. Campath-1H in renal transplantation: The University of Wisconsin experience. Surgery 2004; 136: 754.
11. Huang E, Cho YW, Hayashi R, et al. Alemtuzumab induction in deceased donor kidney transplantation. Transplantation 2007; 84: 821.
12. Sampaio M, Kadiyala A, Gill J, et al. Alemtuzumab versus ilterleukin-2 receptor antibodies induction in living donor transplantation. Transplantation 2009; 88: 904.
13. Ciancio G, BurkeGW,Gaynor JJ, et al.Arandomized trial of three renal transplant induction antibodies: Early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing and newer immune monitoring. Transplantation 2005; 80: 457.
14. Ciancio G, Burke GW, Gaynor JJ, et al. A randomized trial of Thymoglobulin vs. alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in renal transplantation at 24 months of follow-up. Clin Transplant 2008; 22: 200.
15. Farney AC, Doares W, Rogers J, et al. A randomized trial of alemtuzumab versus antithymocyte globulin induction in renal and pancreas transplantation. Transplantation 2009; 88: 810.
16. Hanaway MJ, Woodle ES, Mulgaonkar S, et al. Alemtuzumab induction in renal transplantation. N Engl J Med 2011; 364: 1909.
17. Thomas PG, Woodside KJ, Lappin JA, et al. Alemtuzumab (Campath 1H) induction with tacrolimus monotherapy is safe for high immunological risk renal transplantation. Transplantation 2007; 83: 1509.
18. Mehrabi A, Mood ZA, Sadeghi B, et al. Thymoglobulin and ischemia reperfusion injury in kidney and liver transplantation. Nephrol Dial Transplant 2007; 22(suppl 8): viii54.
19. Beiras-Fernandez A, Thein E, Chappel D, et al. Polyclonal antithymocyte globulins influence apoptosis in reperfused tissues after ischemia in a non-human primate model. Transpl Int 2004; 17: 453.
20. Chappell D, Beiras-Fernandez A, Hammer C, et al. In vivo visualization of the effect of polyclonal antithymocyte globulins on the microcirculation after ischemia/reperfusion in a primate model. Transplantation 2006; 81: 552.